Votrient

(Pazopanib)

ApprovedSmall molecule

Pazopanib is used to treat certain types of cancer, including advanced kidney cancer and soft tissue sarcoma. It works by blocking proteins that help cancer cells grow and form new blood vessels.[2] Votrient is currently approved and in use across 16 indications[4].[1]

Votrient is one of 216 small molecule programs targeting Kidney Cancer. It is currently in Approved.

Indications

240

Total Trials

Active Trials

215

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Kidney CancerCompleted

Renal Cell CarcinomaCompleted

Malignant Solid NeoplasmsRecruiting

Neuroendocrine TumorActive, not recruiting

TreatmentRecruiting

Clear Cell Renal Cell CarcinomaActive, not recruiting

Advanced Soft-Tissue SarcomaActive, not recruiting

Soft-Tissue SarcomasRecruiting

Renal Cell Carcinoma (RCC)Recruiting

Metastatic SarcomaTerminated

Kidney CancerPhase 3

Completed

Renal Cell CarcinomaApproved

Completed

Malignant Solid NeoplasmsPhase 2

Recruiting

Neuroendocrine TumorPhase 2

Active, not recruiting

TreatmentPhase 2

Recruiting

Clear Cell Renal Cell CarcinomaPhase 3

Active, not recruiting

Advanced Soft-Tissue SarcomaPreclinical

Active, not recruiting

Soft-Tissue SarcomasPhase 1

Recruiting

Renal Cell Carcinoma (RCC)Phase 2

Recruiting

Metastatic SarcomaPhase 2

Terminated

Showing 10 of 15 indications

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Votrient

Novartis

Approved

3 2

Emtriva

Gilead

Preclinical

1 3

Lamprene

Novartis

Preclinical

1 4

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 5

Theo-Dur

Pfizer

Preclinical

1 6

Foscavir

CClinigen, Inc.

Preclinical

6 7

Sirturo

WWim Janssens

Preclinical

1 8

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Reminyl

WWim Janssens

Preclinical

1 10

Clomid

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Soft Tissue Sarcoma

NCT02180867

Q2 2027

Phase 2Recruiting

Treatment

NCT06739395

Q2 2028

Phase 3Recruiting

Renal Cell Carcinoma

NCT03592472

Q3 2030

Phase 1/2Recruiting

Glioblastoma Multiforme

NCT02331498

Clinical

Trials by Indication[1]

Renal Cell Carcinoma22 trials

Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma

Completed·SSpanish Oncology Genito-Urinary Group·Phase 1/2·NCT01513187·53 enrolled

Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)

Completed·TTechnical University of Munich·Phase 3·NCT01613846·544 enrolled

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma

Terminated· Novartis logo

Novartis·Phase 2·NCT01545817·74 enrolled

Show 19 more trials

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 2·NCT01147822·367 enrolled

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5

Completed·CCancer Trials Ireland·Phase 2·NCT01566747·43 enrolled

An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma

Completed· GSK logo

GSK·Phase 1·NCT00992121·11 enrolled

Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis··NCT01649778·662 enrolled

Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

Completed·—·Phase 1·NCT01221506·20 enrolled

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Completed· Novartis logo

Novartis·Phase 3·NCT01235962·1,538 enrolled

Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control

Terminated·AAIO-Studien-gGmbH·Phase 2·NCT02959554·49 enrolled

Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

Completed· Novartis logo

Novartis·Phase 1·NCT02014636·42 enrolled

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Completed·IInstitut Claudius Regaud·Phase 4·NCT02555748·47 enrolled

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01361113·21 enrolled

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01472081·194 enrolled

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00731211·57 enrolled

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

Completed·IiOMEDICO AG·Phase 4·NCT01521715·44 enrolled

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Completed·—·Phase 1·NCT02406521·30 enrolled

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

Completed· Novartis logo

Novartis·Phase 2·NCT03200717·62 enrolled

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Recruiting·XXynomic Pharmaceuticals, Inc.·Phase 3·NCT03592472·413 enrolled

Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT02729194·16 enrolled

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Completed· GSK logo

GSK·Phase 3·NCT00334282·435 enrolled

Pazopanib in Second-line Therapy in Renal Cell Carcinoma

Unknown status·AAssociació per a la Recerca Oncologica, Spain·Phase 2·NCT01577784·27 enrolled

Soft Tissue Sarcoma13 trials

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01418001·5 enrolled

Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib

Terminated·GGWT-TUD GmbH·Phase 4·NCT03735758·11 enrolled

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Completed·UUniversity of Washington·N/A·NCT01446809·23 enrolled

Show 10 more trials

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Terminated·UUniversity of Washington·Phase 1/2·NCT03660930·19 enrolled

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

Completed· GSK logo

GSK·Phase 3·NCT00753688·369 enrolled

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2/3·NCT02180867·140 enrolled

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Completed·WWashington University School of Medicine·Phase 2·NCT02300545·56 enrolled

A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma

Completed·HHannover Medical School·Phase 2·NCT01861951·120 enrolled

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Completed·UUniversity of Vermont·Phase 1/2·NCT01719302·6 enrolled

Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma

Terminated·HHeidelberg University·Phase 2·NCT01543802·21 enrolled

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Completed· GSK logo

GSK·Phase 2·NCT00297258·148 enrolled

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

Withdrawn· GSK logo

GSK·Phase 2·NCT02367651

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Withdrawn·NNYU Langone Health·Phase 2·NCT03149120

Kidney Cancer9 trials

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1/2·NCT01684397·51 enrolled

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Terminated·—·Phase 2·NCT03334409·5 enrolled

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Completed·—·Phase 2·NCT01158521·25 enrolled

Show 6 more trials

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01664182·41 enrolled

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Completed·—·Phase 2·NCT01157091·28 enrolled

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Completed·MMayo Clinic·Phase 2·NCT01767636·38 enrolled

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

Terminated·UUniversity of Chicago·N/A·NCT01599832·20 enrolled

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Terminated·VVirginia Commonwealth University·Phase 1·NCT02795819·6 enrolled

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT01064310·169 enrolled

Ovarian Cancer8 trials

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer

Completed·IImperial College London·Phase 1·NCT01608009·16 enrolled

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Unknown status·JJSehouli·Phase 1/2·NCT01600573·68 enrolled

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

Terminated·TThe Christie NHS Foundation Trust·Phase 1/2·NCT02055690·21 enrolled

Show 5 more trials

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

Completed·PPriv.-Doz. Dr. med. Joachim Rom·Phase 1/2·NCT01238770·10 enrolled

Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer

Completed·NNational Cancer Institute, Naples·Phase 2·NCT01644825·72 enrolled

Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer

Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 2·NCT01262014·28 enrolled

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Completed·LLinda R Duska·Phase 2·NCT01610206·148 enrolled

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT02383251·118 enrolled

Breast Cancer7 trials

Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00450879·19 enrolled

Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 1·NCT01498458·9 enrolled

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Terminated·UUniversity of Arizona·Phase 2·NCT01394211·2 enrolled

Show 4 more trials

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00849472·101 enrolled

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Completed·—·Phase 2·NCT01466972·30 enrolled

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00347919·189 enrolled

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00509587·21 enrolled

90 more indications

Patients With Advanced Solid Tumors5 trials

S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

Withdrawn·SSWOG Cancer Research Network·Phase 1·NCT00788580

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00619424·58 enrolled

GW786034 in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00060151

Show 2 more trials

Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors

Completed·UUNICANCER·Phase 1·NCT01165385·35 enrolled

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Terminated·RRutgers, The State University of New Jersey·Phase 1·NCT01407562·34 enrolled

Patients With Solid Tumors4 trials

Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00929903·55 enrolled

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00516672·30 enrolled

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT01012362·31 enrolled

Show 1 more trial

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Completed·UUniversity of Illinois at Chicago·Phase 1·NCT01639911·28 enrolled

Non-Small Cell Lung Cancer4 trials

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT01208064·102 enrolled

Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer

Completed· GSK logo

GSK·Phase 2·NCT00871403·107 enrolled

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Completed· GSK logo

GSK·Phase 1·NCT00866528·30 enrolled

Show 1 more trial

Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer

Withdrawn·LLoyola University·Phase 2·NCT01179269

Small Cell Lung Cancer4 trials

Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

Completed·HHellenic Oncology Research Group·Phase 2·NCT01713296·58 enrolled

Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Terminated·NNorthwestern University·Phase 1·NCT01060514·8 enrolled

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Completed·—·Phase 2·NCT01253369·33 enrolled

Show 1 more trial

GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line

Terminated·IIllinois CancerCare, P.C.·Phase 2·NCT01049776·32 enrolled

Advanced Solid Tumors4 trials

Pazopanib and ARQ 197 for Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01468922·32 enrolled

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00678977·22 enrolled

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00722293·111 enrolled

Show 1 more trial

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00732420·68 enrolled

Age-Related Macular Degeneration3 trials

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Completed· GSK logo

GSK·Phase 2·NCT01134055·510 enrolled

12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

Terminated· GSK logo

GSK·Phase 2·NCT01362348·19 enrolled

A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration

Completed· GSK logo

GSK·Phase 1·NCT01154062·15 enrolled

Thyroid Cancer3 trials

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Completed·UUniversity of Washington·Phase 1·NCT01413113·6 enrolled

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00625846·152 enrolled

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01236547·123 enrolled

Treatment3 trials

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT06739395·300 enrolled

Combined Modality Treatment of Sarcomas of the Extremities

Completed·TThe Netherlands Cancer Institute·Phase 1·NCT01985295·12 enrolled

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Unknown status·CCentre Leon Berard·Phase 3·NCT04741438·96 enrolled

Gastrointestinal Stromal Tumor3 trials

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Withdrawn·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT02342600

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)

Completed·CCentre Leon Berard·Phase 2·NCT01323400·81 enrolled

Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

Completed·SScandinavian Sarcoma Group·Phase 2·NCT01524848·72 enrolled

Prostate Cancer3 trials

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00486642·23 enrolled

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00454571·37 enrolled

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

Completed·UUniversity of Utah·Phase 2·NCT01832259·30 enrolled

Refractory Solid Tumors3 trials

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Unknown status·SSamsung Medical Center·Phase 1/2·NCT03628131·46 enrolled

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT01130623

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Recruiting·TTianjin Medical University Second Hospital·Phase 1/2·NCT06895733·65 enrolled

Gastric Cancer2 trials

FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer

Completed·—·Phase 2·NCT01503372·75 enrolled

Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer

Terminated·HHellenic Oncology Research Group·Phase 1/2·NCT01716546·51 enrolled

Melanoma2 trials

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

Completed·UUniversity of California, Irvine·Phase 2·NCT01107665·60 enrolled

Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel

Completed·UUniversity of Zurich·Phase 2·NCT01666418·19 enrolled

Gemcitabine2 trials

Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine

Completed·UUNICANCER·Phase 2·NCT01442662·106 enrolled

Pazopanib Vs. Pazopanib Plus Gemcitabine

Active, not recruiting·NNorth Eastern German Society of Gynaecological Oncology·Phase 2·NCT02203760·58 enrolled

Renal Cell Cancer2 trials

A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer

Withdrawn·—·N/A·NCT02307474

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02560012·4 enrolled

Advanced Solid Malignancies2 trials

A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

Terminated·NNew Mexico Cancer Research Alliance·Phase 1·NCT01542047·3 enrolled

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Completed·AAmsterdam UMC, location VUmc·N/A·NCT01636908·43 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Unknown status·NNational Taiwan University Hospital·Phase 2·NCT01377298·45 enrolled

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

Completed·WWashington University School of Medicine·Phase 1·NCT01716416·32 enrolled

Angiosarcoma2 trials

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Completed·FFox Chase Cancer Center·Phase 2·NCT01462630·29 enrolled

Evaluation of Votrient in Angiosarcoma

Terminated·HHeidelberg University·Phase 2·NCT02212015·26 enrolled

Glioblastoma2 trials

Pazopanib in Treating Patients With Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00459381·35 enrolled

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Withdrawn·CCenter Trials & Treatment·Phase 1·NCT03275558

Urothelial Cancer2 trials

Pazopanib and Vinflunine in Urothelial Cancer of the Bladder

Completed·PProf. Dr. Thomas Otto·Phase 1/2·NCT01265940·5 enrolled

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Completed·SSandy Srinivas·Phase 2·NCT01108055·43 enrolled

Primary Peritoneal Cancer2 trials

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00866697·940 enrolled

Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women

Completed· GSK logo

GSK·Phase 2·NCT01227928·145 enrolled

Cancer2 trials

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

Unknown status·UUniversity Medical Center Groningen·Phase 4·NCT05949424·30 enrolled

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

Completed· GSK logo

GSK·Phase 1·NCT00363194·28 enrolled

Relapsed or Refractory2 trials

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Completed·UUniversity of California, San Francisco·Phase 1·NCT03139331·16 enrolled

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Unknown status·SSamsung Medical Center·Phase 2·NCT02638428·90 enrolled

Glioblastoma Multiforme2 trials

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Recruiting·CCentre Antoine Lacassagne·Phase 1/2·NCT02331498·51 enrolled

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01931098·35 enrolled

Lung Cancer2 trials

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01027598·202 enrolled

Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01262820·15 enrolled

Metastatic Sarcoma2 trials

Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients

Terminated·TThe Netherlands Cancer Institute·Phase 2·NCT02575066·25 enrolled

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT02601209·151 enrolled

Liposarcoma2 trials

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Completed·VVector Oncology·Phase 2·NCT01506596·42 enrolled

Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 2·NCT01692496·52 enrolled

Metastatic Melanoma1 trial

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00861913·13 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Completed·NNorthwestern University·Phase 1/2·NCT01465659·29 enrolled

Fallopian Tube Cancer1 trial

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1/2·NCT01402271·88 enrolled

Neuroendocrine Cancer1 trial

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00454363·52 enrolled

Nasopharyngeal Cancer1 trial

Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00454142·33 enrolled

Bladder Cancer1 trial

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01031875·41 enrolled

Uterine Cancer1 trial

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01247571·22 enrolled

Single Dose1 trial

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

Completed· GSK logo

GSK·Phase 1·NCT00659555·24 enrolled

Paraganglioma1 trial

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01340794·7 enrolled

Metastatic Urothelial Cancer1 trial

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00471536·19 enrolled

Bone Sarcoma1 trial

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Completed·NNorthwestern University·Phase 2·NCT02357810·178 enrolled

Metastatic Renal Cell Cancer1 trial

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Completed· GSK logo

GSK·Phase 3·NCT00387764·80 enrolled

Solid Tumors1 trial

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01454804·43 enrolled

Advanced NSCLC1 trial

Pazopanib in Molecularly Selected Patients With Advanced NSCLC

Terminated·WWashington University School of Medicine·Phase 2·NCT02193152·16 enrolled

Advanced1 trial

Pazopanib as Single Agent in Advanced NETs

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT01280201·44 enrolled

Advanced Malignant Tumors1 trial

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

Completed·MManisha Shah·Phase 1·NCT01713972·23 enrolled

Malignant Pleural Mesothelioma1 trial

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00459862·34 enrolled

Elderly1 trial

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

Completed· GSK logo

GSK·Phase 1·NCT00463320·29 enrolled

Fallopian Tube1 trial

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01468909·106 enrolled

Tolerance1 trial

PAZOPANIB Efficacy and Tolerance in Desmoids Tumors

Completed·IInstitut Bergonié·Phase 2·NCT01876082·72 enrolled

Von Hippel-Lindau Syndrome1 trial

Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01436227·32 enrolled

Neovascular AMD1 trial

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

Completed· GSK logo

GSK·Phase 2·NCT00612456·70 enrolled

Phase II1 trial

Pazopanib Maintenance Phase II

Terminated·LLudwig-Maximilians - University of Munich·Phase 2·NCT02207309·1 enrolled

Penile Carcinoma1 trial

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Terminated·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT02279576·4 enrolled

ESS1 trial

Study To Assess Long Term Safety Of Pazopanib

Completed· Novartis logo

Novartis·Phase 1·NCT00387205·188 enrolled

Salivary Gland Carcinoma1 trial

Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

Completed·UUNICANCER·Phase 2·NCT02393820·72 enrolled

SCLC1 trial

Pazopanib Maintenance for SCLC

Completed·SSamsung Medical Center·Phase 2·NCT01797874·97 enrolled

Hereditary Hemorrhagic Telangiectasia1 trial

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

Unknown status·CCure HHT·Phase 1/2·NCT03850730·30 enrolled

Resistance1 trial

Rotating Pazopanib and Everolimus to Avoid Resistance

Completed·NNetherlands Working Group on Immunotherapy of Oncology·Phase 2·NCT01408004·101 enrolled

Osteosarcoma1 trial

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

Terminated·EEmerald Clinical Inc.·Phase 2·NCT01759303·12 enrolled

Chondrosarcoma1 trial

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Completed·EEmerald Clinical Inc.·Phase 2·NCT01330966·47 enrolled

Trial1 trial

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

No longer available·TTracon Pharmaceuticals Inc.··NCT02354612

Metastatic Colorectal Cancer1 trial

Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

Completed· GSK logo

GSK·Phase 1·NCT00540943·25 enrolled

Torsades de Pointes1 trial

Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

Completed· GSK logo

GSK··NCT01446224·1 enrolled

Urothelial Carcinoma1 trial

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01622660·2 enrolled

Terminated·WWashington University School of Medicine·Phase 2·NCT01080248·2 enrolled

Solitary Fibrous Tumor1 trial

Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 2·NCT02066285·96 enrolled

Liver Cancer1 trial

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Completed· GSK logo

GSK·Phase 1·NCT00370513·28 enrolled

Advanced Cancers1 trial

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00674024·8 enrolled

Uterine Leiomyosarcoma1 trial

Pazopanib for Treating Uterine Leiomyosarcoma

Withdrawn·GGynecologic Oncology Group·Phase 2·NCT02378142

Efficacy and Safety1 trial

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

Completed·SSpanish Oncology Genito-Urinary Group··NCT02282579·300 enrolled

Carboplatin1 trial

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Completed· GSK logo

GSK·Phase 1·NCT00388076·86 enrolled

Frail Elderly Patients1 trial

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Terminated·IInstitut Claudius Regaud·Phase 1·NCT01642017·18 enrolled

Treatment Outcome1 trial

Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

Completed·RRadboud University Medical Center··NCT01995981·22 enrolled

Prospective1 trial

Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT04462445·25 enrolled

Fibrosarcoma1 trial

Phase II Pazopanib Study in Advanced Dermatofibrosarcomas

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01059656·23 enrolled

Pembrolizumab1 trial

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Completed· Incyte logo

Incyte·Phase 3·NCT03260894·129 enrolled

CRC1 trial

pazopanib_NCRCC,Ph2 STUDY

Completed·SSamsung Medical Center·Phase 2·NCT01538238·10 enrolled

Protein Kinase Inhibitors1 trial

Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors

Unknown status·UUniversity Hospital, Grenoble·N/A·NCT03571438·100 enrolled

Cervical Cancer1 trial

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

Completed· GSK logo

GSK·Phase 2·NCT00430781·228 enrolled

Chemotherapy1 trial

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

Completed· GSK logo

GSK·Phase 2·NCT00561795·12 enrolled

Corneal Neovascularization1 trial

Treatment of Corneal Neovascularization With Topical Pazopanib

Completed·RReza Dana, MD·Phase 1/2·NCT01257750·20 enrolled

Metastatic Prostate Cancer1 trial

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Terminated·IIllinois CancerCare, P.C.·Phase 2·NCT00945477·11 enrolled

Lymphedema1 trial

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Completed·KKathy Miller·Phase 2·NCT00827372·10 enrolled

Malignant Glioma1 trial

Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

Completed· GSK logo

GSK·Phase 2·NCT00350727·75 enrolled

Advanced Cancer1 trial

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01548144·178 enrolled

Advanced Urothelial Cancer1 trial

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Completed·—·Phase 1·NCT01184326·23 enrolled

Acute Myeloid Leukemia1 trial

Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible

Completed·UUniversity Hospital Muenster·Phase 2·NCT01361334·20 enrolled

Adenocarcinoma1 trial

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Terminated·SSCRI Development Innovations, LLC·Phase 1/2·NCT01035658·22 enrolled

Recurrent1 trial

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

Completed·VVector Oncology·Phase 1·NCT00800345·33 enrolled

Unspecified8 trials

Hepatic Monitoring for Pazopanib

Completed· GSK logo

GSK··NCT01449825·1 enrolled

Dose Escalation Study of Pazopanib Plus TH-302

Completed·HHerbert Hurwitz, MD·Phase 1·NCT01485042·50 enrolled

A Study of Pazopanib With CAPEOX in AGC Patients

Completed·SSamsung Medical Center·Phase 2·NCT01130805·66 enrolled

Show 5 more trials

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

Completed· GSK logo

GSK·Phase 4·NCT01205230·34 enrolled

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT01072214·37 enrolled

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01430572·62 enrolled

An Extension to Study MD7108240

Completed· GSK logo

GSK·Phase 2·NCT00733304·42 enrolled

VEG111485: A QTc Study of Pazopanib

Completed· GSK logo

GSK·Phase 1·NCT00861029·2 enrolled

Regulatory

FDA Approval Timeline[5]

Oct 19, 2009

VOTRIENT

NDA NDA022465

Sources

References

[1]
ClinicalTrials.gov — 240 trial records for Pazopanib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Votrient drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Pazopanib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Pazopanib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022465). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Fibroblast Growth Factor Receptor 1 Inhibitor; Fibroblast Growth Factor Receptor 3 Inhibitor; Macrophage Colony Stimulating Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase ITK/TSK Inhibitor; Tyrosine-Protein Kinase LCK Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Votrient

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q2 2028

Q3 2030

Trials by Indication[1]

Renal Cell Carcinoma22 trials

Soft Tissue Sarcoma13 trials

Kidney Cancer9 trials

Ovarian Cancer8 trials

Breast Cancer7 trials

Patients With Advanced Solid Tumors5 trials

Patients With Solid Tumors4 trials

Non-Small Cell Lung Cancer4 trials

Small Cell Lung Cancer4 trials

Advanced Solid Tumors4 trials

Age-Related Macular Degeneration3 trials

Thyroid Cancer3 trials

Treatment3 trials

Gastrointestinal Stromal Tumor3 trials

Prostate Cancer3 trials

Refractory Solid Tumors3 trials

Gastric Cancer2 trials

Melanoma2 trials

Gemcitabine2 trials

Renal Cell Cancer2 trials

Advanced Solid Malignancies2 trials

Head and Neck Squamous Cell Carcinoma2 trials

Angiosarcoma2 trials

Glioblastoma2 trials

Urothelial Cancer2 trials

Primary Peritoneal Cancer2 trials

Cancer2 trials

Relapsed or Refractory2 trials

Glioblastoma Multiforme2 trials

Lung Cancer2 trials

Metastatic Sarcoma2 trials

Liposarcoma2 trials

Metastatic Melanoma1 trial

Pancreatic Neuroendocrine Tumor1 trial

Fallopian Tube Cancer1 trial

Neuroendocrine Cancer1 trial

Nasopharyngeal Cancer1 trial

Bladder Cancer1 trial

Uterine Cancer1 trial

Single Dose1 trial

Paraganglioma1 trial

Metastatic Urothelial Cancer1 trial

Bone Sarcoma1 trial

Metastatic Renal Cell Cancer1 trial

Solid Tumors1 trial

Advanced NSCLC1 trial

Advanced1 trial

Advanced Malignant Tumors1 trial

Malignant Pleural Mesothelioma1 trial

Elderly1 trial

Fallopian Tube1 trial

Tolerance1 trial

Von Hippel-Lindau Syndrome1 trial

Neovascular AMD1 trial

Phase II1 trial

Penile Carcinoma1 trial

ESS1 trial

Salivary Gland Carcinoma1 trial

SCLC1 trial

Hereditary Hemorrhagic Telangiectasia1 trial

Resistance1 trial

Osteosarcoma1 trial

Chondrosarcoma1 trial

Trial1 trial

Metastatic Colorectal Cancer1 trial

Torsades de Pointes1 trial

Urothelial Carcinoma1 trial

RCC1 trial

Adjuvant1 trial

Pancreatic Cancer1 trial

Solitary Fibrous Tumor1 trial